Therapeutic strategies aimed at reactivating the mechanisms limiting TAZ hyperactivation and/or inhibiting TAZ/YAP oncogenic effects might be highly beneficial for treating human iCCA. The gene discussed is YAP1; the disease is infantile convulsions and choreoathetosis.